Hashimoto H, Abe M, Tokuyama O, et al. - Since olanzapine 10 mg added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone was recommended for the prevention of chemotherapy-induced nausea and vomiting, researchers conducted this randomised, double-blind, placebo-controlled, phase 3 study to test the effectiveness of olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting caused by cisplatin-based chemotherapy. This investigation was conducted in 26 hospitals in Japan. Eligible participants have been randomly assigned (1:1) to receive either oral olanzapine 5 mg or placebo once daily on days 1–4 combined with aprepitant, palonosetron, and dexamethasone. Seven hundred ten individuals (356 were randomly assigned to receive olanzapine and 354 were assigned to receive placebo) were recruited between February 9, 2017, and July 13, 2018. The authors discovered that one patient had constipation of grade 3 and one patient had somnolence of grade 3 related to treatment in the olanzapine group. For patients undergoing cisplatin-based chemotherapy, olanzapine 5 mg combined with aprepitant, palonosetron, and dexamethasone could be a new standard antiemetic therapy.